FDA Approves Lembaz for Infantile-Onset Niemann-Pick Type C, First Treatment Shown to Extend Survival
The U.S. Food and Drug Administration on Tuesday approved Lembaz, an adrabetadex injection, in a milestone for patients with infantile-onset Niemann-Pick disease type C, an ultra-rare and fast-moving neurodegenerative disorder. The agency said the treatment is the first shown to help patients with this form of the disease live longer.
The approval, granted to Mandos, LLC, a subsidiary of Beren Therapeutics, P.B.C., covers adult and pediatric patients who weigh at least 7 kilograms, or about 15 pounds, and whose neurological symptoms began before age 6. That group corresponds to infantile-onset Niemann-Pick disease type C, or NPC, the most rapidly progressive and deadly form of the disorder. NPC is a rare inherited lysosomal storage disease, usually caused by mutations in the NPC1 gene and less often NPC2, that disrupts how cells handle cholesterol and other lipids, especially in the brain.
FDA said it evaluated survival in 36 patients treated with adrabetadex across three clinical studies and an Expanded Access Program. In a pooled analysis comparing those patients with a matched external control group, the agency said treatment was associated with a 55% reduction in the risk of death. Median survival was 8.5 years for treated patients, compared with 4.9 years for controls, according to FDA. The evidence came from pooled clinical-study and expanded-access data matched against external controls, rather than from a large randomized placebo-controlled mortality trial.
That survival signal is especially significant in NPC because earlier neurological onset generally means faster decline and earlier death. The disease causes progressive loss of coordination, swallowing problems, cognitive decline and seizures, and FDA estimates it affects about 1 in 150,000 people.
Lembaz is not a simple therapy. It is administered intrathecally — into the spinal canal — every two weeks by a trained health care provider. The drug also carries a boxed warning, FDA’s strongest safety warning, for hearing impairment, including permanent hearing loss. The agency said patients should receive a comprehensive hearing evaluation before starting treatment and at regular intervals during treatment, and dose adjustments may be needed. The most common side effects reported were hearing problems, balance and coordination problems, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea and cough.
The approval also changes the treatment landscape for the youngest and sickest NPC patients. FDA said that before Lembaz, two therapies had been approved for NPC, but neither had been shown to reduce the risk of death and both had age or weight restrictions that limited access for the youngest, most severely affected patients. In the U.S., arimoclomol, sold as Miplyffa, was approved in 2024 for neurological manifestations of NPC in patients 2 and older, in combination with miglustat. Miglustat has NPC approvals outside the U.S. and is used off-label and in combination in the United States.
Lembaz received Breakthrough Therapy designation during development, a program meant to speed review of promising drugs.
“For families living with Niemann-Pick disease type C, today’s approval marks an important milestone,” Acting FDA Commissioner Kyle Diamantas said in the agency’s announcement. “For the first time, there is a treatment shown to help adults and children with this serious disease live longer, and we are committed to continuing to support the development of therapies for the rare disease community.”